Search

Your search keyword '"Kvist, Kajsa"' showing total 165 results

Search Constraints

Start Over You searched for: Author "Kvist, Kajsa" Remove constraint Author: "Kvist, Kajsa"
165 results on '"Kvist, Kajsa"'

Search Results

1. Applying the causal roadmap to longitudinal national Danish registry data: a case study of second-line diabetes medication and dementia

3. A Causal Roadmap for Hybrid Randomized and Real-World Data Designs: Case Study of Semaglutide and Cardiovascular Outcomes

4. A Causal Roadmap for Generating High-Quality Real-World Evidence

5. Targeted Maximum Likelihood Based Estimation for Longitudinal Mediation Analysis

6. Beyond the Cox Hazard Ratio: A Targeted Learning Approach to Survival Analysis in a Cardiovascular Outcome Trial Application

7. A Cross-Validated Targeted Maximum Likelihood Estimator for Data-Adaptive Experiment Selection Applied to the Augmentation of RCT Control Arms with External Data

8. Case study of semaglutide and cardiovascular outcomes: An application of the Causal Roadmap to a hybrid design for augmenting an RCT control arm with real-world data.

9. A causal roadmap for generating high-quality real-world evidence.

15. Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers

17. Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium–Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes

21. Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes

24. Treatmentwith glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.

33. Association Between Glucagon-Like Peptide 1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Use and COVID-19 Outcomes.

38. Development of a hypoglycaemia risk score to identify high‐risk individuals with advanced type 2 diabetes in DEVOTE.

39. Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE.

40. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

42. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

45. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.

46. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).

Catalog

Books, media, physical & digital resources